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1.  INTRODUCTION 
1.  Continuing concerns about the quality, safety and efficacy of blood and blood products in the 
European  Community  motivated  the  European  Commission  to  recommend,  in  its 
Communication of  December 1994
1
, the development of  a Community  blood strategy in order  t~ 
improve confidence in the safety of  the blood transfusion chain and to promote Compmnity self-· 
sufficiency, The Council m  its Resolution of  June 1995
2 invited the Commission to continue its 
efforts to  define such a strategy using as a basis  ~e  activities it had proposed.  In November 
1996, Cowicil's Resolution
3 on a Strategy Towards Blood Safety and Self-sufficiency in the 
European Community further refined the constituent elements of  the strategy by calling 'for a co.:. 
ordinated approach to the safety ofblood and blood products, and calling on the Commission to 
submit proposals as a matter of  urgency, drawing upon the ConClusions and Recommendations 
of  a Colloquium on blood safety and self-sufficiency held in Adare, Ireland.
4 Responding to thi~ 
invitation,  the Commission has been pursuing. activities  to  advance  the  dev~lopment of this 
·strategy and as a frrst step has concentrated on the need for common requirements regarding the 
-·  suitability ofblo()d and plasma donors and the testing of  their donations. Such requirements _can 
make a significant contribution to ensuring the quality and safety of  needed blood and plasma, 
restoring  the  confidence  of  Community  citizens  in  the  blood . transfusion  system,  and  . 
contributing to the continuing efforts to achieve Community self-sufficiency tiirough voluntary · 
unpaid donations. 
2.  THE BLOOD TRANSFUSION CHAIN 
2.  The  blood  transfusion- chain  comprises  an. exten~ive number  of complex.  and  interrelated 
activit~es  extending  from  the  willingness  of an  indiviqual  to  provide  blood  or plasma  for 
therapeutic use; through the elaborate precautions taken in the preparation of both labile blood 
components (red blood cells, white blood cells,  platelets and plasma)  and stable industrially-
prepared  .  derivatives  (e.g.  albumin,  clotting -factor  concentrates,  protease  inhibitors  and 
immunoglobulins); to  the  ~administration of any of thC?Se  products to-a patient and subsequent 
follow-up.  Each of  these steps requires meticulous attention to safety. 
.  .  . 
3.  One of the most crucial links  in  this chain,  however,  are  the  requin!ments  for  ensuring the·. 
2 
acceptance· of  an individual as a blood or plasma donor and those for testing the donated blood 
or pla-sma  f()r  infectious diseases.  As the Commission noted in its -1994  Communication, the -
. donor  selection  process  differs  across  the  Community  and  "it  would' be  beneficial  if an 
agreeinent  -is reached as regards the rules arid practices (or donor selection, including new and 
repeat donors as well as donors ofwhole blood,  ~ellular components and plasma, to be ·applied 
across the Community''. It also referred. to  the differing testing requirements that exist in  th~ 
Communication from the  Commission  on  Blood  SafetY  and  Self~sufficiency in  the  European  Community. 
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O.J. No Cl64. 30.6.95. p.l 
O.J. No C374. 1 Ll2.96. p.l  .  .  . 
4  Department of Health,  Ireland.  Conclusions  and  Recommendations.  Colloquium  on Blood  Safety  and  Self-
sufficiency: An Agenda for the European Community. Adare, County Limerick, Ireland. 4-6 September 1996. 
.  .  1 Community  hindering  the  transfer of blood  and  the  free  movement  of blood products  and 
impeding  the  goal of self-sufficiency in blood and plasma as  starting material  used  for  the 
preparation of medicinal products.  These existing variations among the Member States of the 
European Community contribute to a lack of  confidence not only among patients but among the 
blood establishments themselves.  · 
4.  Donor selection. and the screening of donations were among the topics discussed at the Adare 
Colloquium by Member States experts who recommended, inter alia, that existing guidelines on 
donor selection be reviewed "with a view to making proposals for common criteria to be used in 
the European Community'' and that "a minimal set of  screening tests should  ·apply in all Member 
States for the testing of whole blood and components  for  transfusion as well as plasma for 
· . fractionation". Moreover, they stressed the ':1-eed for criteria at Community level regarding donor 
identification and determining the core elements and risk behaviours that should be identified 
through a donor screening questionnaire. 
· 5.  In order to establish the basis for common criteria, the Commis~ion in early 1997  conducted~ 
survey of the current regulations and practices in the Member States regarding the selection of 
donors and the screening of  their blood donations. This survey addressed the current legislative 
requirements  in the Member States and guidelines of the Council of Europe and the World 
Health Organization; the criteria for the selection of whole blood and plasma donors; elements 
covered  in the  donor questionnaire  and  physical  examination;  the major reasons  for  donor 
deferral for the safety of recipients;- the current screening tests required for  individual whole . 
blood donations  and plasma obtained through  apheresis;  and the interpretation of a reactive 
result  in the  initial  screening test  for -infectious  agents  (e.g.  HIV,  HBV,  HCV,  syphilis)  in 
relation to the clinical use of  the donation. The outcome of  the survey, which was discussed at a 
· meeting of national experts in June  1997,  and the deliberations  at the  meeting itself clearly 
reflected variations in regulations and practices in the· Member States. The results of the survey 
are being·presented in a working paper of  the Coriunission Services entitled "The suitability of 
blood and plasma donors and the screening of  their donations: a 1997 survey of the regulations 
and practices in the Member States of  the European Community". 
3.  EXISTING AND PROPOSED REQUIREMENTS 
6.  Directive  89/381/EEC
5  extended  the  scope  of pharmaceutical  legislation  to  encompass  the 
quality,  safety and efficacy requirements for industrially prepared medicinal products derived 
from blood and plasma but specifically excluded whole blood, plasma and blood cells of  human 
origin. In respect of  measures covered by the modification as to testing requirements, referred to 
in Article 6 of  that Directive, to be taken by" the Member States to prevent the transmission of 
infectious  diseases  by blood and plasma used as  a  starting material  for  the  manufacture of 
medicinal  prod~cis, Article  3  refers  to  the  application of the  monographs of the  European 
Pharmacopoeia  and to recommendations  by ·the  Council  of Europe  and  the  World  Health 
Organization as regards in particular the selection and testir1g of  blood and plasma donors. The 
Directive makes  no provision for  adaptation to  requirements  recommended  or published on 
donor selection that may have arisen after its adoption in 1989 nor to  s_cientific  and technical 
progress.  Moreover,  since  Article' 1(2)  of the Directive specifically excludes  whole blood, 
plasma or blo€>~ cells of  human origin from its scope, difficulties may arise in practice when 
the final destination of  the donation is not known. 
5  O.J. No Ll81, 28.6.89, p.44 
2 7.  Council.Decision 94/35S/EC
6 accepted o~ behalf of the European Community, the Convention 
on the elaboration of  a European Phannacopoeia which aims to harmonise quality specifications 
for  active  substances  and  excipients  in  order  to  facilitate  the  free  circulation  of medicinal 
products  in  the  countrie~  party  to  the  Pharmacopoeia.  This  harmorusation  simplifies 
phannaceutical and biological testing requirements for marketing authorisations. The European 
Phannacopoeia's monograph on 'Human Plasma forFractionation' makes only a reference to 
Council of  Europe recommendations regarding the selection of  donors which are therefore not 
mandatory. 
8.  Council  Directive  95/46/EC
7  addresses  the  protection  of individuals  with  regard  to  the 
·processing of personal data and the free movement of such data. This Directive requires that . 
certain sensitive  data in particular that  related to  the  health of an  individual be subject to-
. reinforced protection. It covers only personal data and not that rendered  anonymous~  so that 
the person is no  longer identifiable. Processing of medical data is prohibited unless the data 
subject'  gives· his  explicit  consent..  This  prohibition  is  not  applicable,  however,  if the 
processing  of the  data is  for  the  purpose _of preventive  medicine,  medical  diagnosis,  the 
provision of care  and  treatment or'  the  management of health  serVices,  and  the- data are 
processed by a health profess~onal subject to the obligations of  professional secrecy.  · 
9.  At  the  level  of the  Member  States,  the  Comniission's  survey  highlighted  the  significant 
variations  in  legislative  requirements regarding  the  selection of donors  and  the  testing_ of 
donations. These range from  extensive· and detailed legislation developed in recent years, to 
regulations dating to  1980, to  non-binding national guidelines. Legislative revisions  in the 
area  of blood  are currently underway in two  Member  States.  These  variations  hin.der  the 
transfer of blood (and plasma)_ and the  free  movement of blood and plasma products,  thus 
impeding the achievement of  Community self-sufficiency. 
1  O.Therefore,  L'1  keeping with the goal of making a contribution towards ensuring a high level of 
health protection to the citizens of the Comrimnity,  and  providing for  the attainment of self-
sufficiency  in  blood  and- plasma  through  voluntary  unpaid  donations,- and  in  view  of the  .  - . 
variations both in legislation and practice in  the Member States, the Commission considers it 
imperative  that  common requirements be  introduced by  all  Member States based on agreed 
recommendations. These should be based on the outcome of its survey and the latest scientific 
evidence regarding  the determination of the  suitabilitY  of donors  and  the  screening of their 
donations. As stated in a recent report by the Swedish National-Working Group on Blood Self--· 
sufficiencl "many European- citizens  do  not  trust  the  quality  and  safety  of blood products _ 
originating from  countries other than their own. Only by iJ?plementing common standards can 
we increase the-trustbetween Community Member States,  enhan~e the free movement of  blood 
and 'blood products,  and reach the goal of Community self-sufficiency".  These requirements · 
must, pursuant to  Article 129 of the EC Treaty, be based on Council recommendations, which 
should aim at promoting sound practices and consistency throughout the Community without 
being dispmportionate with regard to the overall objectives being pursued, namely the safety and 
sufficiency in the Community of blood and plasma and the health protection of the donors. To 
that  end,  ~he  proposed  recoinmendations  should  address  donor  suitability  and  eligibility, 
volumes collected, and the screening of  samples of  donated blood, and should be congruent with_ 
the provisions of  Directive 89/3 81/EEC. 
6  O.J. No L158, 25.6.94, p.70. 
O.J. No L281. 23.11:95. p.31 
Swedish National  Working  Group  on Blood  Self-sufficiency.  European  self-sufficiency  in  blood and  blood 
p'roducts: Balancing supply and demand. Background Paper to the statement by the Swedish Minister of Health 
and Social Affairs, Margot Wallstrom, (Health) Council Meeting, Luxembourg, June 5 1997. 6p.- .  -~  34  ..  __  ..  . 4.  DONOR SUITABILITY 
ll.Ascertaining the  suitability of an individual who  has  offered to  donate blood or plasma is 
essential in order to ensure that there are no detrimental effects to the prospective donor's health 
and to protect that of  future recipients of  the blood products emanating from that donation. The 
initial step in this process is _the  provision of accurate and understandable information to the 
prospective donor about the benefits and hazards, both to their own health and that of future 
recipients, associated with blood and plasma donation. Agreement by the prospective donor of  a 
willingness to proceed should be followed by the identification and registration of  the donor, the 
recording of this information ·in  an appropriate data  file~ the verification of certain physical 
parameters, and the compilation of  a medical history to identify and screen· out those who may 
be at some health risk either to themselves or to recipients of  their donation.  · 
12.Although the true effeCtiveness ofwritten  qu~stionnaires in scr~g  out donoci with high risk 
behaviours  has  not  yet  been  fully  demonstrated,  and  the  need  for  a  Communit}l.:.wide 
comprehensive· and common questionnaire not established due especially to cultural differences 
in the Community, it is essential that several core dements and risk behaviours· be addressed 
during the pre-donation process. These should be addressed in the written questionnaire, or the 
interview with a trained health care staff  member, or both and should cover a number of  diseases 
and conditions, as well as certain risk factors,  on which there is solid scientific consensus for 
their inclusion. 
13:Acceptance  criteria  for  donors  of whole  blood  and  apheresis  plasma  should  be  clearly 
established to  ensure that there are no  detrimental effeets to the donor's health and additional 
criteria need to be imposed for the protection of future recipients of  the blood products deriving 
from their donation. Donors, who for one of  many reasons. may be deemed ineligible to donate. 
blood  either  temporarily  or  permanently  should .be  given  appropriate  counselling.  The 
discretion of  the physician is paramount in the final determination of  eligibility of  a donor. 
.  ~ 
5.  DONOR INELIGIBILITY 
14.A  prospective  donor  may  be  considered  ineligible  to  donate ·blood  or  plasma,  either 
temporarily or  permanently~ at any time _during the donation process. Such individuals are said 
to be "deferred" and the period of time during which ·they are considered ineligible varies 
according to  different factors ..  It is important that appropriate records of such deferrals are 
· maintained  in  such  a  way  that  while  the  confidentiality  of t!le  data  is  maintained,  the 
information is accessible to authorised individuals whether at a donation site or when matters 
of safety are concerned. Such manual or computerised records are often referred to as donor 
deferral registers (DDR). 
15.The survey of  the requirements and practices in the Member States revealed general agreement 
regarding permanent deferral for particular situations such as HIV I AIDS, hepatitis C, syphilis, 
etc  .. Temporary deferral ~howed both commonality among Member States for SO!De situations, 
and considerable  variation for  oth~rs. For example,  temporary  deferral  ranged  from  6  - 12 
months for tattoos; 2 - 5 years after recovery from tuberculosis; 1 - 2 years after recovery from · 
·toxoplasmosis; from "each service I doctor has own criteria" to 5 years 'for hepatitis A. These 
variations appear to· reflect an absence of conclusive scientific data about the tinie frame  for 
deferral of  donors on which sound decisions can be made. Supplementary survey information 
submitted to the' Commission following the meeting of experts also reflected the variations in 
practices. In order to arrive at. suggested common criteria, therefore, a mean time frame of th(( 
5. responses received is proposed.  The  scientific basis upon which these deferral periods are 
made must be kept under r~view. 
16.In those siW:ationswhere a donor is defe~ed temporarily, provisions must be made to allow 
him I her to be c,onsidered for donation again at the end of  the deferral period.  · 
· 6.  DATAPROTECTION 
17  .Although the measures taken by Member Stfites to ensure. the protection of data related to a 
blood or plasma donor were not addressed in the Co~ission  survey, relevant requirements 
are laid down in Dire~ctive 95146/EC. Measures to ensure positive donor identification,· the 
verification· of data,  safeguards  against unauthorised. access  to  information,  data additions, 
deletions  or  modifications,  data  irreguiarities,  and  discrepancies  and  the.  security  of 
·confidential data all need to be taken into account.  This is particularly applicable in cases 
where an individual is deferred. 
- .  .  . 
18.Article8 of the Directive refers to the proce~sing 9f special categories 'of data  incl~ding that 
conceminghealth._According to this Article, the processing of  such data shall be prohibited in·· 
the Member States. It establishes, however, certain cases in which this prohibition shall not  ·  · 
apply  su~h as When the data subject lias given his I her. explicit consent to the processing of 
those data,  when the data proces-sing is  req~ired for the purposes of-preventive medicine, 
medical  diagnosis,  the  provision of care  or treafment  or  the  management  of h~alth 'Care 
services, and where those data are processed by a health professi<,>nal subject under national 
law or rules establ~shed by national competent bodies to th.e obligationof professionalsecrecy 
or by another person  also subject to an equivalent obligation. The Article also establishes that 
Member States may, for reasons of substahtial,public interest, lay dowri  exemptions to. the 
proh1bition with such measures notifiable to the Commission.  ·  · 
7.VOLUMESCOLLECTED 
19.The maximum amount ofwhole blood or plasma collected from a donor at any one sitting._and · .... 
over a 12 month period, the time interval between-the donations, and the a!Jowable frequency  ·.  · 
. · over a given time period have been established in order to prevent any adverse effects.to the 
health of  the donor as a consequence of  the donation. For whole blood~ the maximum volume 
. collected  during  an  individual  donation (450  ml ± 10%) and  the  minimum time interval 
between donations (8  weeks) are practically the same in all the Member States and .  are in 
keeping  with  recomp1endations  of the  Council  of Europe  (1997)  and  the  World .Health 
Organization  (1994).  Two  Member  States  as  well  as  the  standards  of the  American 
Association of  Blood Banks (AABB), however, permit a higher volume (500- 525 ml), 
I  •  .  ~ ..  • 
20.For apheresis-plasma: the mi:lximum volume collected during an individual' donation and over 
a 12 month period varies among the Member States- from 550 t() 650 ml per donation; Q.5.to 
1 litre per week; and 10 to 2:5 litres per year. The frequency of  donations varies between twice 
per week and twice a·month and the maxim~  number of  donations varies between 4 and 50 
peryear. This wide variation may be attributed in part to the differences between manual and . · 
automated phismapheresis. ·  · 
21.As a significant volume of  plasma and plasma products; sourced from donors. who are paid, is 
importedinto the Community from the United States,of America, it has to be noted that the 
allowable maximum plasma volume per individual donation, and _over a 12 month time frame, 
6 are  higher  i.ti  the  US~ than  those  currently  permitted  in  several  Member  States.  The 
maximum volume of plasma allowed per donation in the USA depends  in practice on the 
weight of the  donor:  625  ml  for  donors  weighing  between  50-67  kg;  750  ml for  donors 
weighing between 68-79 kg; and 800 ml for those weighing 80 kg or more. 
27.According  to  the  1997  report  of the  Swedish  National  Working  Group  on Blood  Self-
sufficiency, "the volume of  plasma collected is based mainly on theoretical calculations about 
how much fluid can be lost without risk to  th~ donor.  In the US where the body size of the 
donor- is  used  to  determine· the  allowable  volume,  the  donor's  blood  status. has' been 
s·ystematically monitored without detecting disturbances." 
.  -
· 2?.In view of the Community's goal  of self-sufficiency and  the  lack of progress towards  it, 
serious consideration has  to  be  given to  allowing  an  increase  in the  maximum allowable 
volumes of plasma currently prevailing in the Member States. This would contribute to the 
goal of self-sufficiency. The view espoused by some that higher volumes are detrimental to 
the health of the donor does  not  appear to  be substantiated by scientific evidence.  On the 
contrary,  the United States Department of  Health and Human  Service~ stated in  1992  in a 
· memo
9  to  licensed  source  plasma establishments  that  "An analysis  based on comparison 
between the allowable volume of source plasma derived from whole blood collected during 
·manual  plasmapheresis .and  the  experience  to  date  with  all  of the  approved  equipment 
(automated plasma collection devices) indicates that there is no discernible impact on donor 
safety, or product quality with the use of  the current limits in preference to any other". 
24.Until  scientific evidence is  adduced to  show  that permitting an increase in  the  volume of 
blood or plasma collected from a donor or reducing the time interval between donations has a 
detrimental effect on the  donor's  health,  and  in view of the benefits  for  Cortnnunity self-
sufficiency, it is proposed that increased volumes such as those accepted in the United States 
scheme be recommended for application by the Member States. Programmes using increaJed 
volumes should be monitored closely to ensure that no detrimental effects accrue to the donor. 
8.  SCREENING OF SAMPLES OF DONATED BLOOD · 
25.Whether it is a donation of  whole blood or components intended for transfusion purposes or· 
plasma collected through apheresis and intended for transfusion or further manufacturing into 
medicinal  products, .  sample  specimens  of the  blood  taken  from  the .  donor  at  the  time  of 
collecting  the  blood  and  plasma  should  be tested  for  markers  of infections  that  can  be 
transmitted t<;>  recipients. In order that the citizens of  the Community have the highest degree of 
confidence in the safety of the blood  and blood products administered  for  therapy, Member 
States should apply the same screening tests to the common source for both whole blood and 
components used for transfusion,a.'l.d plasma· used for fractionation with one exception, namely 
when plasma is collected by plasmapheresis for the sole purpose of  fractionation-some tests, may 
not be required because the virus is not transmitted by plasma-derived products. 
26~  The survey showed that whether the donation is of  whole blood or plasma, almost all Member 
States require a sample of  the donor's blood to be tested for ~tibodies against the hepatitis C 
virus (~ti-HCV), antibodies against the human immunodeficiency virus type 1 and 2 (anti-
9 
Department of Health  and  Human  Services.  FDA.  Memo  to  All  licensed  Source  Plasma  Establishments.  4 
November 1992.  · 
7 HIV  ·r  and 2), the surface antigen of the hepatitis B virus (HBsAg), and syphilis. With the 
e~ception·  of syphilis,  · this  reflects . the . mandatory  requirements  of, the _  European 
Pharmacopoeia monograph on· 'Human Plasma for Fractionation'  for- all blood and plasma 
donations used as SOUrCe matenal for the preparation of industrially manufactured medicinal 
products.  As syphilis is not. transmissible  by plasma-derived products,  the  Biotechnology 
Working Party of  the Committee for Proprietary Medicinal Products (CPMP) advised in.l995 ·_ 
that this ·test is not required for plasrria for  fnictionation
10 ~  Only one Member State does·not 
test for syphilis.  ·  · /  · 
27.Requirenients  for  other  ·tests  for  markers  of· various  diseases  transmissible  by ·blood 
. transfusion vary. among the Member States. A malaria test is generally not. required but five  . 
Member ·States· allow for  it ''when required" or· required "for travellers to  endemic areas". 
TestingJor antibodies to human T-celllymphotropic virus (anti-HTLV I and ll)-is carried out 
In six Member St(ltes ~ith.  Oile indicating that it is carried out on first time donors and another 
reporting that although not required, it is done. Testing for hepatitis B core antibodies (anti-
HBc) is carried out in five Member States for whole blood donations with three requiring it 
only fot first time donors. HIV p24 antigen test is not required in any of the Member States: 
but is a pilot project in one,_Only one Member State requires neopterin testing for whole blood 
donations.·  .. 
'.·  - .  .  .  .  - •  .  .  .  .._  .  .  .  .  I .. 
28.The survey substantiated  earli~r reports regarding tests that are required in some Member 
States and not in others leading· to  impediments on the utilisation of excess plasma, the free 
movement·. of plasma-derived  products,  and  therefore.  to  a  lack of progress  towards 
Community self-sufficiency  .. This  difficulty  ·arises  particularly  with  reference  to alanine. 
aminotransferase  (AL  T)  which  is  not  required  by  the. European  Pliarmacopoeia.  Plasma 
collected by some Member States that has not undeq~onethis test is rejected for use by others. 
It  .is noteworthy that an expert  pan~l at the National Institute of Health of the United States 
recommended that its use be discontinued since, as shown by scientific data, it had outlived its 
usefulness .and was of little value now .given the availability. of the HCV .·test. This view was 
reiterated by the experts to.the Adare Colloquium who  considered that ALT screening had 
become redimdant because of  the specific screening for.HBsAG and antibodies to hepatitis C. 
' 
,· . 29.It · follows.  from  the  above  that·· a  set  of . scientifically-based ·arid·· broadly-supported . 
requirements, as well as  a procedure for'inaking decisions, depending on the results of the 
various  tests  th"!t  donated  blood  ~ndergoes,  ..  should  be  established  based  on  agreed 
recommendations  for the Community.  .-
.  9~ ·cOMMON TERMINOLOGY 
· 30.A fundamental requirement for  arriving at common criteria related. to the suitability of donors 
and·  the··  testing  of  donations  is . the  use  ·of  common  terminology  .. · Confusion  and 
misunderstandings o'ften arise as a result of  different interpretations ofthe same terminology. In_-
. spite of  the existence of  several gl~ssaries, there is still no consistent use of  several terms hi ,this 
sector  such -as .blood products,  repeat donors,  etc.  Therefore  common  terminology  for  use 
throughout the Community is proposed.  · 
10 
DGIII/5941194: "Sele'ction and screening of  donors for blood I plasma as starting material for.medlcinal products. 
Position paper for CPMP on  'harmonisation of  selection and screening of donors/exclusion criteria" in" Inventory · · 
. of  Provisions relating to Medicinal Products Derived from Human Blood or Plasma':, Brussels, March 1995.  · 
8  ' 10.  SCIENTIFIC COMMITTEE AND REPORTING 
31.The dynamic and rapidly-evolving environment of  transfusion medicine, such as cytapheresis,. 
total blood apheresis and cord blood collection as well as the questions posed by the availability 
or introduction of  new technologies such as ge~ome.~plification  technology (GAT)- a highly · 
sensitive  technique  capable  of detecting  viral  genonies  even  when  serological  tests  aie 
negative  - as  a:  possible  screening test,  demands  that  mechanisms· be in place  for  the 
Community to have ready access to scientific and technical guidance and be able to respond 
quickly to changing technology and scientific information. Consideration will be given by the 
Commission to establishing a  Scientific Committee on blood to advise it on these and the 
other matters covered in the proposed recommendation. 
32.Moreover, in order to ensure that all Member States are fully aware of  developments that have 
implications at Community level arid to keep the Council informed of  the measures that. have 
·been  taken  towards  the  implementation- of  common  criteria  in  the  Community,  the 
Commission could prepare r~orts as appropriate  . 
. . 
.  . 
9 ..  ;-
•,  ' 
PROPOSAL FOR A  - · 
COUNCIL RECOMMENDATION . 
·.  . pn the  sui~ability of  blooc1 and plasma donors and · 
the·  scre~ning of  donated·.bloo.d 
.  in the European Community  .. THE COUNC~  OF THE EUROJ,>EAN UNI9N 
'  '  .  ' 
·Having regard to ,the Treaty establishirig the European Community, and in particular Article .129 
thereof;  ·  ·  ·  · 
.  .  • .  .  .  .  .  .  •  •  .  1 
Havmg regard to the  prop~sal from the Corrumss10n ; . 
Having. regard to.the opinion oftl).e European Par~iamene, 
L  Whereas  in accordance  ~th point (o) .of  ArtiCle  3 of the  Tr~ty, Community action ·  musf 
.  .  .  .  .  .  /  .  .  .  .  . 
include a  contribution towards the attainment of  a high lev~l ofP,eal$ protection;  .  .  -
- 2.  Wh~reas the  Co~ission's Conimunication  on  Blood  Safety  and Self-sufficiency  in  the . 
.  E~opean  C~mmunity3 of  December 1994 identified ·the need. for a· blood strategy in order to . 
reinforce co~fidence iri the safety of  the blood transfusion chain .and promote Community self- · 
sufficiency; 
· 3,  Whereas  Council  in its  Resoiution  of 2  June. 1995
4
,  in  response  to  the  Commission's 
,.; . 
Communic~tion,  invited it to submit appropriate proposals· in·the framework of  develo:J?ment of·. 
a blooq strategy; 
. 4;  Whe~eas Colintil in its Resolution of 12  Nov~mber 1996
5 on a strategy towards blood safety 
. and self..,sufflciency in the .Eliropean Community invited the Commission to submit proposals  , 
as  a .matter  pf urgency  with  the. view  to  encouraging  the  development  of a  co-ordinated 
approach to the safety ofblood  ·an.d blood products; 
.  - .  .  .  .  ~  . 
5  .. Whereas the European Parliament in its resolutions on blood safety and self-sufficiency through 
volUntary u'npaid donations in the £urope~  Communit/. 
7 8  9 has stressed .the importance. of 
ensuring the-highest level of safety in the selection of  donors and the testing of donations and. 
· h~  .reiterated its continued support ~or the ·objective of  C~!nmunity_  self-sufficiency; 
6.  Whereas Council Directive 89/381/EEC
10  extended the scope of  pharmaceutical legislation to 
_g'ua:rantee  the  quality,.  safety,  arid. efficacy  of proprietary  industrially  prepared  medicinal 
products derived from .human blood or human plasma; whereas it does not apply. to whqle 
. b,lood, to plasma,·or to blood cells ofhllll?-an origin; 
O.J. - - - - - -· 
. z .  O.J.-----
3  COM (94)652 fina!. Brussels. 21.12.1994 
4  O.J. No Cl64, 30.6.95, p.l 
s.  .  O.J. No C374, U.l2.96, p.l 
6 
O.J: No C268, .4: 10.93, p.Z9\ 
7  O.J. No C329,  6.12:93, p.268 . 
8  O.J. No C249; 25.9.95, p.231 
9  O.J. No C141. 13 5.96. p.l31 
10 
· O.J. No L181, 78.6:89, p.44 
\ 
11 · 7.  Whereas  therapeutic  use  of blood  and  medicinal  products  derived  from  ~uman blood  and 
.  .  .  .  .  - . 
plasmc( contributes  significantly  to  saving  lives  and  yietqs  considerable  benefits  for  those 
suffering  from  long  term  blood  disorders~· whereas,  however,  in· spite of their  significant · 
· therapeutic  value~ blood,  blood  comp~nen~s. and  blood  and  plasma ·  d~rivatives have  the 
. potential to  transrriit infectious-diseases; 
8.  Whereas the availability of blood· and plasnia used for therapeutic purposes and as. starting 
matenal  for. the· manufilcture · of medicinal  products  is  dependent  on the  willingness  and 
. generosity of  Community citizens-who are prepared to donate;  · 
9.  Whereas donations should be voluntary and unpaid; 
10. Whereas in respect of  blood or plasma as a starting material for the m;u;_ufacture .of proprietary 
medicinal products, Article 3 of  Council Directive 89/381/EEC refers to measures: covered by 
the modification, as to testing requirements, referred to in Article 6 of  that Directiye, to be taken 
by Member States to prevent-the transmission 9finfectious diseases, coinpri~ihg the applic'atioh 
of  the monographs of  the European Pharmacopoeia and'the reconunendations of  the Council of 
Europe aild the,World Health Organization as regards in particular  the selection and testing of · 
.  .  .  . 
blood and plasma donors; to  promote Coriununity self-sufficiency in human ·blood or human 
plasm:a; and to encourage yoluntary unpaid donations of  blood and plasma;  · 
'  .  .  .  . 
11. WhereaS it is riot always possible to  kiJ,ow  at  the time of  whole blood or plasma collection 
'  .:.  ~  .  '  . 
which donation may be used for further manufacture rather than used in transfusion; · 
12. Whereas all blood and plasma used for therapeutic purposes, whether for transfusion or for 
further manufactUre into industrially-prepared medicinal products,. should be obtained from  . 
. individuals whose health status is such as to ensure that transmission of  disease does nottake 
.  pl~ce, and that each and  every blood donation should be tested· in accordance. with rules 
which provide assurances that all necessary measures have been takento safeguard the health 
;:"  .  .  ...  .  ' 
of  Community citizens who are the recipients of  blood and blood products; 
.  - .  .  -
13. Whereas  given  th~t the  blood  transfusion  systems  in  the ·Member  States  of the  European 
Community exist to serve its citizens; it is necessary to secure their. confidence in the safety o·f 
.  these systems; 
14. Whereas  djspanties  m  policies  and  practices  among the  Member  States· regarding  the 
selection of donors  and  the  screening of donations  within the 'Community are  such as. to 
.  - .  -·  .  .  .  -· 
·  -~.mdermine confidence among  _it~ citizens as well as blood tnmsfusion services in the safety of 
the bloo<J and blood products and hinder the achievement ~f  self-suffici~ncy; . 
12 15. Whereas the goal of Community self-sufficiency can only be achieved through co-operation 
among the Member States in order to overcome such disparities and build mutual confidence in 
all aspects of  safety ofthe·blood transfusion chain; 
.')yf  16. Whereas the suitab~lity ·of an indivi<;lual to donate blood and pl~a  is an essential d,mponent 
in contributing to the safety ofbloo.d and blood products and to the goal of  self-sufficiency; 
'  .  .  -
17. Whereas it is essential that all measures be taken to safeguard the health of  those who provide 
their blood and plasma and to minimi~e the hazard of  transmission ~f  infectious diseases by 
blood or blood products; 
18.-whereas uniformity and consistency throughout the Community in the acceptance of donors, · 
the screening of donations and the recording of  relevant data will help. to contribute to !}le 
achievement of self-sufficiency and to increasing confidence in the safety of  blood and plasma 
· donations_  and the transfusion process;  whereas in order to  bring about such uniformitY and 
consistency, and build confidence, measures are required at Community level; 
19. Whereas  measures  at  Community  level  should  take  into  account  existing  guidelines, 
.  . 
· recommendatioll.s and standards in the area of  blood at both national·and international levels;. 
.  . 
20. Whereas in accordance with the principle of subsidiarity, any new measure taken in an area 
which  does  not  fall  within  the  exclusive  competence  of the  Community,  such  as  donor · 
suitability ~d  testing of  donations, may be taketi up by the Gommunity only if, by reason of  the 
· scale  or effects of the proposed action,. the objectives of the proposed action can be better 
achieved by the Community than by Member States; Whereas commonly agreed requiiemeQ.ts 
on donor suitability arid  tes!ing of donations need,. therefore, to be introduced in order to 
. contribute to the safety of  donated blood and plasma and the health protection of  donors and 
. to permit confidence in safety of the transfusion chain among citizens,  especially as they 
move  about  in the Commuriity",  and  to  contribute to the  attaiiunent of Community self- . 
sufficiency as provided for in Community legislation; 
·  '21. Whereas  in accordance with the principle  of proportionality, .  the means  to  be deployed  at 
Community level for promoting sound practices and consistency throughout the Community in 
the suitability of blood and plasma donors  and the  screening of donated blood must be. in 
proportion to the objective pursued; 
22: Whereas  rec~mmendations by the Councii, pursuant to Articie 129 of the EC-Treaty, are the· 
appropriate means for doing so at Community level; whereas such reco'mmendations must b~ 
congruent with the provisions ofDirective 89/381/EEC; 
13 I. 
I 
·  ...... 
.  23. Whereas recommendations on donor suitability and testing requirements fonn part of  a strategy 
to enhance  s~ety: of the blood transfusion chain, the other elements of which include the 
inspection  and ·accreditation  of blood  collection  e~tablishmenfs, requirements  related  to 
'  -
quality assurance of the processes involved,  theopt~mar  use of blood and blood products, 
haemovigilance, and public awareness;  . 
.  !  1 
24. Whereas it is necessary that the ~est possible scientific advice lS available to lhe Community iri 
relation to t\le-safety of  blood and blood products;  · 
r 
25. WhereaS Directive 9-5/461EC
11  on the protection of  indivi~uals With regard to the processing_ 
i 
of  personal data and the free movement of such data lays down speCial requirements for the  r 
.processing of  data _concerning health; 
HEREBY RECOMMENDS THAT 
1.  J)EFINITIONS 
'  ,'  '  '  ·,  '  '  \  '  '  '  ' 
For the purpose of  this Recommendation, Member States  ass~gn to the tenns listed~in Al?nex l  the 
·.  - '  . 
meaning given to them therein; 
2._PROVISlON OF INFORMATION TO PROSPECTIVE DONORS 
. Member States pr<~vide to all prospective donors cifblood or plasma: 
2.1  For donor awareness 
. II 
a.  Acc~rate but generally  und~rstandable  ·educational materials about the essential nature of·· 
....  -- .  .  ·- .  '  . 
blood, the products derived from  it,. and the important benefits to  patients :or  blood and 
plasma donations; 
1J.  The reasons  for  requiring  a  medical history,  physical  e~amination, and  the  testing of 
donations; information ·on the risk of infectious diseases that may be transmitted by blood 
and blood prod~cts; the .signs and symptoms of_ AIDS, and the significance of  'informed 
consent'' self-deferral: and temporary and perinanent deferral;  ' 
c  .. The reasons why they should not donate which may be detrimental to their own health; ·  · 
d.  The reasons why they should not donate which put _recipients at risk, such as  ~nsafe sexual 
b~haviour, IHV  I  AIDS, hepatitis, ~rug addiction and the use and abuse of  drugs; ·  · 
e.  The option cif changing their mind about donating prior to .proceeding further without any 
undue embarrassment or discomfort; 
-..:__ 
·'' 
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'4 f.  Information on the. possibility of withdrawing· or self-deferring  at any  time  during the 
donation process; 
g.  The  ·opportunity to ask questions at any time; 
h.  The undertaking th~t if  test results shows evide_nce of  any pathology, they will be contacted 
by the· blood collection centre; 
1.  Speyific information on the nature of  the procedures involved in the donation process and 
· associated risks  for  those  willing .  to  participate  in apheresis  programmes,  whether for 
plasma or cellular components. 
2.2  Confidentiality 
a.  The measures taken to .ensure the confidentialitY of: any health-related information provided 
to the authorised health personnel, the results of  the tests on their donations, as well as any 
future traceability of  their donation; 
b.  The assurance that all interviews with prospective donors are carried out in pnvate; 
c.  The option of  requesting the medical staff of  the ·blood collection centre not to use his I her 
donation. 
3.  INFORMATION REQUIRED FROM PROSPECTIVE DONORS ·  .  . 
Member_ States ensure that,  upon agreement of a willingness to  proceed to  donate blood or 
plasma, all prospective donors (whether first time~ new, repeat or· regular) provide to the blood 
and plasma collection establishment: . 
3.1  Identification  -
Identification, supported by valid official documentation ·providing name (first and surname), 
address, and date ofbirth. 
3.2  He;tlth history 
a.  ·Information pn their health and medical history including .any relevant social and behavi~ural 
characteristics that may assist in identifying and screening out persons whose donation could 
present a higher risk of  transmitting infections as well as those who could have contracted a 
recent infection that may not yet be detectable in the screening tests; 
b.  Answers  to  questions  about  their  health. and  medical  history ·by  way  .of  a  written 
questionnaire  and  a  personal  interview with a  trained  health care  staff member which 
·  ~  should address the elements· ail  d. risk behaviours ·listed in Amlex 2: 
c.  Their signature and that of  the health care staff member conducting 'the_ interviews on the 
donor questionnaire acknowledging that the educational materials provided have been read 
15 - r 
and un_derstood,  the  opportunity to  ask. questitm_s  has  been  presented,  and. satisfactory 
· responses have _be_en received; 
3.3  -Informed conse:Qt _ -
a.  Their mfopned cons(mt in writing that they wish to proceed with ~e  donation process; 
b.  The prospective donor's agt;eement  thatif~eirblood or plasma donation bec~mes excess 
to the nee~s of  their own Member ~tate,- it m~y  be shared with another Member State  .of  the 
-Community that is in  need; ..  · 
.  '  -~ 
·4.  REGISTRATION OF DONOR 
. Member States, in order to  faCilitate  future. verification of repeat  arid  ~egular do~ors, future 
·_  tracing  ofdonati~ns. and  future  exch~ges of infonriatiol\  e~tablish a 'mutually  col11p~tiblff 
.  .·  ..  .  . 
do~or  identification I registration systep1 to:  _  · 
· 4.1  :Ponor centre identification 
a.  Permit .. every . domition .  centre  in  each  Member  State  to  .  be  uruquely  identified,  ·by 
. comrrumicating to all other Member  States and to the Commission a list of  centres and their 
identification comprising the country code and a suitable· combination of  letters and numb~rs 
:at their discretion; 
4.2  Do~or  identification .and registry 
a.  Require tl].at ·an relevant information regarding the identification  ofprospecti~e donors be . 
•  ::_  '  •  ,  •  '  •  •  •  r 
recorded in an automated or manual system for new and first_  thne donors and be verified . 
prior to eac_h 'donation: for repeat and regular donors; 
b.  Provide for the keeping of records on donors and prospective donors in such a way as  to 
ensure 'unique identification, protect the  identity of the donor from  unauthorised access to 
·.confidential information, but faciiitate future traceability of  any d~nation; 
c.  Allow-for the inclusion of information related to adverse donor reaction to the donation, 
reasons for preventing ail individual from donating, whether on a temporary or pennane~t 
basis while, ensuring confidentiality. 
5.  - DONOR SUITABILITY 
.·  Membe~  States, in or~er to ensure the suitability. of individuals to be  a~cepted as  donors of  blood 
. and plasma: 
· 5.1·  Suitability criteria  fo~ the acceptanceofwhole bl~od  and apheresis plasma donors 
- .  .  . .  . 
a.  Ensure that general criteria for the acceptance of  blood and plasma donors are clearly ·spelt 
out in every donation  cent~~ and that clear messages are presented ·to  donors . as  to the 
importance oftheirWillingness to donate but also the importance ofthe  acceptance·crit~ria; · 
\6 . ·, 
' 
.  b.  Ensure that the responses given to the 'Issues raised in the Written questionnaire and I or the  .  . 
personal interview,  as  presented in Annex. 2,  pro:.nde .  the  neCessary  confi4ence that the 
donatio~  will not adversely affect the health of  a future recipient of  the productS derived from 
that don~tion; 
c.  E~lire that the .  prospective  dorior  meets the physical  ~equirements criteria contained  in 
Anne~  3 in order that there are no detrimental effects to .hls I her own· health as the result ~f 
the donation; 
· d.  Ensure thatthe prospective donor's suitability is deterlhined at each donation session; 
e:  ;Prohibit or phase out the practice of  using 'replacement donors';· 
f.  ReqUire  the responsible physician to  give .his I  her written  authorisation  as  to  the fmal 
determination of  the suitabilitY of  a prospective donor, when this may be questionable. 
6 ..  ··  DONOR iNELIGIBILI'fY 
Member States, in order to ensure that the prospective donors do not cause harm to thefr own health 
· nor that their donation present a risk ·of  traiismission of  infectious diseases: . 
6.1  Deferral criteria forwh~le  blood and apheresis phisma donors 
a.  Emmre those who  may show evidence of  one of  the characteristics listed in Annexes 4 and·  • 
.  5  should be rendered either permanently or temporarily ineligible to 'donate blood and 
plasma; 
.  .  .  .'  .  ~ 
b. Ensure that-appropriate provisions are in_place in  the donation centre for counselling, as 
•  •'  t 
appropriate, to prospective donors who are ·deferred. 
· 6~2  Deferral registers 
a:· Maintain a  record of any  ~rospective· donor deferral, ·whether permanent or temporary, 
including the reasons why; 
b.: Ensure  that ·such  donor  deferral  registers  are. set  up  so  as . to  fully  respect  data 
.· confidentiality requirements but be ·available for consultation by authorised personnel of. 
.  . 
the blood,collection establishment or appropriate  authoriti~s when  matte~s of safety are .. 
~oncemed. 
7.  . DATA.PROTECTION 
~ember  States, in order to ensure the confidentiality of S<?nsitiv·e medical information about 
'p~dspective donors: 




-·  ·I K Ensure that data security measures are in place as well as safeguards against unauthorised.-
data additions; deletions or modifications to donor files oi deferral registerS, and. transfer of  ·  .  .  .  .  .  . 
information; 
c.  Ensure that procedures are 'in place to resolve data discrepancies; 
,. 
d.  Pievent the unauthorised disclosure of  such information, while erisuri:ng -the. traceability of 
· donations; 
e.  Pay particular attention ·to  co~pliance with the  requirements of Directive 95/46/EC .in 
particular its Article 8, when processing data related to blood and plaSma don~rs. 
8.  VOLUMES COLLECTED FOR SAFETY OF DONOR 
. To protect the health ofthe donor, Member. States: 
a.  Adhere to the maxirrium volumes of blood and plasma collected at a single donation  ~md 
over a 12 month period presented i'u Annex 6; 
·b.·· Adhere to the minimum time intervals between.donations ~presented  in·Annex 6; 
c.- Ensure that medical attention is available to  the donor in the event of an adyerse event· 
related to the donation. 
9.  TESTING SAMPLES OF DONATED ·BLOOD 
·Member States, in order to ensure the safety of  allblood and plasma, do~ations: . 
a.  EI}sure_tliat a  sample of all  donations  whether intended for  transfusion purposes  or for 
further manufacturing into industrially prepared medicinal products is tested for diseases 
'transmissible by blood 'using  licensed  screening .  tests to eliminate units  that  are  repeat .. 
reactivej_ · 
b., Ensure that all blood donations be found non-reactive for the tr_ansmissible disease markers 
listed in Annex 7; 
c.  Require re-testing of the blood samples found to be reactive in an initial screening test in 
'  '  . 
' accordance with the general-~lgorithm setout in  Annex 8; 
10.  ADDITIONAL MEASURES 
a.  Member:States take the necessary steps for the dissemination·ofthis recommendation to all . 
, parties concerned, artd in particular to blood establishments in their territory; 
'  / 
b.  Member States take all necessary measures to encourage the voluntary and unpaid donation 
.  ' 
of  blood or plasma; 
INVITES THE COMMISSION 
To report on the application of  these recommendations and  ke~p the matters covered therein under  ·_ 
review in order to take the necessary steps for revision and updating. 
Done at Brussels  .  18 
For the Council 
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ANNEXJ. 
Common Terminology 
'Whole. blood collected  from  a  single  donor and processed either for  transfusion or 
.  · further manufacturing  "'  · 
Any therapeutic product derived from human whole blood or plasma donations. 
Therapeutic components of  blood (red cells, white cells, plasma, plateleu;) that can be 
prepared  by centrifugation,  filtration,  and  freezing  using  conventional  blood .bank 
·methodology. 
Highly  purified  hunian  plasma  protein  prepared  up.der  licensed  pharmaceutical 
manufacturing conditions. 
\. 
A therapeutic product derived from a blood component  (as derived from leukocytes 
- interferon, cytokines - or from outdated erythrocytes - haemoglobin solution) 
· Someone who has never donated either blood or plasma. 
Someone who; for protection of  their own health: or that of  potential recipients ·of blood 
products prepared from his l her donation, is not permitte4 to give blood or plasma. 
Someone who routinely had .donated blood or plasma (regular donor) and has stopped 
presenting himself I herself to donate.  · 
Someone who has not donated blood or plasma within the last year or is not listed in 
·the local donor registry. 
-Someone  who  presents _  himself  I  herself  at  a  blood  or  plasma  collection 
establishment and states hiS I her w~sh  to give blood or plasma  .. 
Someone who  has  donated before  and within the  last year in  the  same  donation 
centre. 
Someone  who  routinely  donates  their  blood  or plasma  at  the  permissible  time 
intervals. 
Donors recruited by patients to enable them tci undergo elective surgery. 
Medicinal product derived from blood or plasma. 
·  ·  Same meaning as· in Directive 89/381/EEC 
Suitability 
Personal data 
Process by which an acceptance_ decision of a prospective blood· or plasma donor 
can be made. 
· Any infom1ation relating to an identified or  identifia~le natural person who can be 
identified,  directly  or  indirectly,  in  particular  by  reference  to  an  identification 
number or to one or more factors to his physical, physiological, mental, economic, 
cultural or social identity. (Directive 95/46/EC)  · 
Voluntary, unpaid blood donation 
slime meairing as in Directive ~9/381/EEC . ANNEX2  .. 
-Common Elements to be Covered in a Donor Questionnaire . 
.  .  .  . ..  , 
· •  Indication that 'the questionnaire is to be completed, signed and dated · 
•·  Genenil health of  the donor 
•  .  Whether prospective donor · 
•  has recently consulte-d a doctor 
•  . is taking any medication  ' 
· •  has haemophilia or related blood ~lotting disorders 
•  participates in hazardous sports (e.g. motor racing) 
• · undertakes employment that might cause problems within 24 hours after blood·  donation · 
•  is pregnant or has delivered a child now tinder (year (for women) 
•  has received growth hormone or pituitary extract treatment 
•.. has'  received a  blood transfusion 
• · has had a corneal or dura mater transplant  _ 
•  has undergone tattooing, acupuncture, body piercing by someone other than qualified and I or 
licensed professional  .  ·  .  - . 
•  has been in recent contact (<3 weeks) with contagious infections, chicken pox, measles 
•  has recently received a vaccinatiop(polio, tetanus, holiday vaccinations)  · 
•  has recently (<5 days) ingested aspirin.(  or other pai!l killers) 
•  is working as a prostitute_ 
•  is HIV positive  . 
•- has a  spouse who is HIV positive 
•  has a family history of  Creutzfeldt-Jacob disease (CJD) 
•  self-injects drugs 
• · Whether prospective donor-bas/ had 
•  Brucellosis · 
•  Epilepsy 
•  Hepatitis 
•  Jaundice 
•  Major surgery/seriou~ illness . 
·.  •  Malaria 
o.  Whether prospective donor h::J,s p-avelled 
•  Outside Western Europe & NorthAriu;:rica 
•  Men who have. sex with other men . 
•  Sexual activity in Africa · . · 
•  Sexual a_ctivity in countries oth~r than those in Africa: (to specify country) 
•  Self-exclusion option 
•·  TI1e ques.tionn_eire has to be given and compJeted at every visit. . 
. 20 ANNEX3 
Common Acceptance Criteria for Blood and Plasma· Donors 
Age·  . 
Blood and plasma donors should be 18- 6S years of  age. Acceptance of  first time donors age60-
6S  is at the discretion of the responsible physician. Repeat donors may continue to donate after 
the age of  6S with the permission of  the responsible physician given annually. 
For whole  blood,  donors  aged  17,  an'd  not  legally  classified  as  minors,  may  be  accepted; 
otherwise writtel.l consent should be required according to applicable law  . 
. Body weight 
Donors weighing no less th'"an SO kg may donate whole blood or plasma. 
Blood pressure 
The systolic blood pressure  should not exceed  180  mm of mercury and the  diastolic  pressure 
should not exceed 100 mm of  mercury. 
·- Pulse 
The pulse should be reguiar and between  50- 110 beats per minute. Those prospective donors who 
· undergo  intensive sport training and have a pulse rate  lower than  SO  beats per minute_ may be 
accepted. 
· ·  Haeliu;,globin  ·  _ 
The haemoglobin concentration should be determineq prior to donation and shall be no less than 
12.S g/100 ml for females and 13.S gl100 ml for males (or equivalent values expressed in mmoll 
1). For apheresis plasma donors, the minimum shall be 12.5 g/100 ml for both males and females. 
Haematocrit 
.The packed cell volume (haematocrit) should be determined prior to donation and shall be no less 
. than 38% for females  and 40% for males. For apheresis plasma donors, the minimum shall be 
38%. 
Donation interval  . 
For whole bl~od, the time interval between donations sho'uld be greater than 8 weeks. 
For apheresis plasma, this interval should not be less· than 72 hours. 
Donation frequency  .  .  . 
For whole blood, the maximum number oftirries allowable for donations should be 61 year"for 
men, 4 I year for women and 3 I year for pre" menopausal donors.  · 
For apheresis plasma; the maximum donation frequency should be twice per week, 
:2..\ Common Deferral Criteria for Blood and Plasma Donors 
(For protection of  donor) 
1.  Permanent deferral 
Prospective  donors  with  any .or  a  history  of any  of  the  following  should  be  declared  peiJ11anently 
ineligible to donate blood or plasma for the protection of  their own health:  ·  '  · 
•  Auto-inuilune diseases 
•  Cardiovascular diseases 
•  Central nervous system diseas~s 
•  Malignant diseases  · 
•  Abnormal bleeding tendency 
•  Fainting spells (syncope) or convulsions 
Permanent  deferral  in  cases  where  prospective  donors  have  or  have  had  a  severe  or  chronic 
gastrointestinal, haematological, metabolic; respiratory,  or renal  disease, not included in' the pre-ceding 
categories,. should be determined by a qualified physician in the blood collection establishment. 
2..  Temporary deferral · 
Ineligible for 1 year 
• ·.Abortion 
•  . Pregnancy (after delivery) 
NOTE:  Addition~! reasons may exist for the temporary defe1Tal of a do~or for the protection of  thei~. own 
. health  .. A  decision as to length of time is  at the discretion of a qualified physician in the .blood 
collection establishment. .  ·  · ·ANNEXS 
Common Deferral Criteria for Blood and Plasma Donors 
(For protection of recipient) 
1.  Permanent deferral 
/ 
Prospective donors with any, or a  history of any,  of  the following  should be .declared permanently 
ineligible to donate blood or plasma for the protection of  potential recipients. ·  - .. 
. •  Auto-immune diseases 
•  Infectious diseases- persons suffering or having suffered from 
Babesiosis  · 
Brucellosis 
CreutzfeldtJacob disease (CJD) (persons in whose family this has occurred) 
Hepatitis B (HBsAg confirmed positive)· 
Hepatitis c 
Hepatitis, infectious (ofunexpla.iiled aetiology) 
HIV I AIDS 
HTLV I III 
Leprosy  . 
Kala Azar (leishmaniasis) 
Q fever 
SyPhilis  · 
Trypanosoma cruzi (Chagas'.  disease) 
•  Malignant diseases 
•  Alcoholic, chronic 
• · Cornea I dura mater transplantation recipient 
•  Intravenous (IV) drug use. 
•  Males who have sex with other· males 
•  Pituitary hormone ofhuman origin (e.g. growth hormone) recipient 
•  Prostitutes (male and female)  · 
2. · Temporary deferral 
Prospective donors with any of the following conditions should be declared ineligible to donate blood or 
plasma temporarily. The time interval for deferral varies according to the condition. 
2.1  Ineligible for 3 years 
•  Tuberculosis (after recovery) 
2.2  Ineligible for 1 year 
•  Accidental exposure to blood or blood contaminated instruments 
•  Acupuncture (ifnot performed by a qualified physician) 
•  Blood transfusion recipient· 
•  Body piercing 
•  Drug allergy (after last exposure) 
. •  Tattoo 
•  Toxoplasmosis (after recovery) 
•  Individuals who have had sexual relations with someone infected or at increased risk of 
infection with HBV, HCV, HIV 2.3 •  · Ineligible for 6 months 
•  Mononucleosis irifectiosa (after rec9very) 
•  Surgery, major' 
2.4  . Ineligible for 4 weeks 
~  Following administr!ltion oflive attenuated viral vaccines 
2.5  Ineligible for 48 hours· 
•  Foll'O'\¥ing administration of  killed I inactivated viral I bacterial and rickettsial vaccines 
· •  F.ollowing administration of  vaccines (desensitising)  ·  .  · 
. •  Rabies vaccine (prophylactic administration) 
2.6  Ineligible  (time framevariable) 
•  Hepatitis A 
•  Malaria (does not apply to plasmapheresis donors) 
• . Prescribed medicines 
•  Tropical diseases (other) 
NOTE:  ·Additional  reasons  may exist  for  the  temporary deferral  of a  donor for  the  protection of the 
recipient. A decision as to  lcength of time is at the discretion of a qualified physician in the blood 
collection establishment. 
[ ANNEX6 
Common Vohimes to be colleCted 
and time intervals 
for whole blood and plasma donations 
Whole Blood 
Maximum Volume  .  · per donation 
per consecutive 12 month period 
) 
Minimum time interval between donations 
Maximum number of  donations per 12 month period 
Automated plasmapheresis 
Maximum Volume  per donation  Donor Weight 
Minimum time interval between donations 
Maximum number of  donations per 7 day period 
50-67 kg 
68-79 kg 






(3 for pre-menopausal women)· 







Common Testing Requii·ementsfor all Blood Samples 
.  whether a whole blood or plasma donation 
· . For all blood and plasma donations 
Antibodies to the Hepatitis C virus 
Antibodies to the human immunodeficiency virus 1 . 
Antibodies to the human immunodeficiency virus 2 






~  .  ~  . 
For all, excluding plasmapheresis intended_ «;mly for fractionation. 
ABO group 
· Rh type 
Malaria ·  for travellers to endemic areas 
Treponema pallidum (syphilis) cleared 
.ANNEXS 
Common Algorithm for 
Interpretation of  reactive results in screening tests in relation to 
clinical use of donation and 
Reactive results in supplementary I confirmation tests 
in relation to donor deferral-
.  negative 
donor and donation cleared 
to be informed about previous 
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